Neutral
Pfizer's stock remains steady at $28 following Q2 earnings and FDA vaccine approval.
Pfizer's stock price has remained stable at $28 following the release of its Q2 earnings report and the FDA's approval of its updated COVID-19 vaccine targeting the XFG variant. The company's earnings exceeded analyst expectations, and the vaccine approval is expected to support seasonal revenue.
Key points
- Pfizer's Q2 earnings report showed an adjusted EPS of $0.77 and revenue of $15.03 billion, surpassing analyst expectations.
- The FDA approved Pfizer's updated COVID-19 vaccine targeting the XFG variant, with shipments beginning immediately.
- Pfizer's stock price remains at $28, with a market capitalization of $159.62 billion.
Sources
- Pfizer-Aktie hält nach Q2-Zahlen bei 28,00 DollarAD HOC NEWS · August 28, 2026
- Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 VaccineNasdaq · August 27, 2026
- Pfizer stock trades just below analyst targets as Q2 earnings and guidance shape 2026 outlookAD HOC NEWS · August 25, 2026
- Pfizer (NYSE:PFE) Shares Up 3.7% - Still a Buy?MarketBeat · August 19, 2026
AI-generated from public news sources. Not financial advice.
